Pluristem Therapeutics Completes Large Scale Cell Therapy Formulation for Commercial and Clinical Trial Use

Published: Nov 07, 2012

HAIFA, Israel, Nov. 7, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today the Company has successfully completed the integration and testing of its new scaled-up formulation and manufacturing process to produce high-yield quantities of its Placental eXpanded (PLX) cells for clinical trials and potential commercial use. The increased automation and larger scale process allows the company to produce billions of live cells simultaneously.

Back to news